Advertisement

Thermal chemosensitization of cDDP-resistant cells

  • A. W. T. Konings
  • J. V. E. Hettinga
  • H. H. Kampinga
Part of the Cancer Treatment and Research book series (CTAR, volume 62)

Abstract

The use of selected anticancer drugs combined with local hyperthermia may improve the ability of oncologists to control locally advanced tumors. This article addresses this possibility and especially discusses recent developments in the area of hyperthermic chemosensitization of cis-diamminedichloroplatinum (cDDP) resistant cells. Only in vitro data will be discussed.

Keywords

Resistant Cell Line Xeroderma Pigmentosum Ehrlich Ascites Tumor Human Ovarian Cancer Cell Line cDDP Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58:137–171, 1989.PubMedCrossRefGoogle Scholar
  2. 2.
    Goldie JH, Goldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy, Cancer Res 44:3643–3653, 1984.PubMedGoogle Scholar
  3. 3.
    Fornace AJ, Alano J, Hollandes MC. DNA damage-inducible transcripts in mammalian cells, Proc Natl Acad Sci USA 85:880–884, 1988.CrossRefGoogle Scholar
  4. 4.
    Andrews PA, Murphy MP, Howell SB. Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells, Eur J Cancer Clin Oncol 25:619–625, 1989.PubMedCrossRefGoogle Scholar
  5. 5.
    Kawai K, Kamatani N, Georges E, Ling V. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J Biol Chem 265:13137–13142, 1990.PubMedGoogle Scholar
  6. 6.
    Freeman ML, Meredith MJ, Eisert DR. Failure of chronic glutathione elevation to reduce cytotoxicity produced by exposure to cis-diamminedichloroplatinum(II), ionizing radiation, or hyperthermia. Cancer Res 50:5296–5300, 1990.PubMedGoogle Scholar
  7. 7.
    Bakka A, Endresen L, Johnsen ABS, et al. Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothioneine. Toxicol Appl Pharmacol 61:215–226, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Schilder RJ, Hall L, Monko A, et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45:416–422, 1990.PubMedCrossRefGoogle Scholar
  9. 9.
    Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 2:35–43, 1990.PubMedGoogle Scholar
  10. 10.
    Milan KM, Hunter KJ, Deen DF, Marton LJ. Reduction in cis-diamminedichloroplatinum(II)-induced cytotoxicity, sister chromatid exchange, and DNA interstrand crosslinks in 9L cells treated with the polyamine biosynthesis inhibitor (2R,5R)-6-Heptyne-2,5-diamine, Cancer Res 49:6945–6948, 1989.Google Scholar
  11. 11.
    Hill BT, Shellard SA, Hosking LK, et al. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum(II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int J Rad Oncol Biol Phys 19:75–83, 1990.CrossRefGoogle Scholar
  12. 12.
    Chu G, Chang E. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 242:564–567, 1988.PubMedCrossRefGoogle Scholar
  13. 13.
    Maynard KR, Hosking LR, Hill BT. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA. Chem Biol Interactions 71:353–365, 1989.CrossRefGoogle Scholar
  14. 14.
    Lai G-M, Ozols RF, Smyth JF, et al. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 37:4597–4600, 1988.PubMedCrossRefGoogle Scholar
  15. 15.
    Sekiya S, Oosaki T, Andoh S, et al. Mechanisms of resistance to cis-diamminedichloro-platinum(II) in a rat ovarian carcinoma cell line. Eur J Cancer Clin Oncol 25:429–437, 1989.PubMedCrossRefGoogle Scholar
  16. 16.
    Masuda H, Ozols RF, Lai G-M, et al. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 48:5713–5716, 1988.PubMedGoogle Scholar
  17. 17.
    Scanlon KJ, Kashani-Sabet M, Sowers LC. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine, Cancer Commun 1:269–275, 1989.PubMedGoogle Scholar
  18. 18.
    Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27:4730–4734, 1988.PubMedCrossRefGoogle Scholar
  19. 19.
    Masuda H, Tanaka T, Matsuda H, Kusaba I. Increased removal of DNA bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 50:1863–1866, 1989.Google Scholar
  20. 20.
    Chu G, Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA, Proc Natl Acad Sci USA 87:3324–3327, 1990.PubMedCrossRefGoogle Scholar
  21. 21.
    Donahue BA, Augot M, Bellon SF, et al. Essigmann JM. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(Gpg) and d(ApG)DNA adducts of the anticancer drug cisplatin. Biochemistry 29:5872–5880, 1990.PubMedCrossRefGoogle Scholar
  22. 22.
    Wallner KE, De Gregorio MW, Li GC. Hyperthermic potentiation of cis-diamminedichloro-platinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 46:6242–6245, 1986.PubMedGoogle Scholar
  23. 23.
    Mansouri A, Henle KJ, Benson AM, et al. Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia. Cancer Res 49:2674–2678, 1989.PubMedGoogle Scholar
  24. 24.
    Herman TS, Teicher BA, Carthcart KNS, et al. Effect of hyperthermia on cis-diamminedi-chloroplatinum(II) and (Rhodamine 123)2 [tetrachloroplatinum (II)] in a human squamons cell carcinoma line and a cis-diamminedichloroplatinum(II)-resistant subline. Cancer Res 48:5101–5105, 1988.PubMedGoogle Scholar
  25. 25.
    Neilan BA, Henle KJ, Nagle WA, Moss AJ. Cytotoxicity of hyperthermia combined with bleomycin or cis-platinum in cultured RIF cells; modification by thermotolerance and by polyhydroxy compounds. Cancer Res 46:2245–2247, 1986.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • A. W. T. Konings
  • J. V. E. Hettinga
    • 1
  • H. H. Kampinga
    • 1
  1. 1.Department of RadiobiologyUniversity Medical SchoolGroningenThe Netherlands

Personalised recommendations